Skip to main content
Equibles
NIKA logo

NIKA · Nika Pharmaceuticals, Inc

Track NIKA — free

Use NIKA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NIKA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.41 At close · Sep 7
Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 10, 2026
Market Cap
$431.19M
Shares
1.05B
Volume · Sep 7 2500 Avg daily vol (10 sessions) 1247

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.41 Open$0.41 Day$0.41–0.41 52W close$0.20–0.77 Avg vol 30d5K Short int70 · 0.0% float · 4.7d Short vol100% DataMar 2024–Sep 2026 Filing10-Q · Aug 10

Up next

Latest filing: 10-Q
filed Aug 10, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$78,125
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$337,692
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.5%
Year over year · more shares
Price change (1Y)
-57.2%
Trailing year
Short interest
0.0%
Latest settlement · 4.7 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.7 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −9%
below
RSI (14) 49
neutral
MACD trend Negative
52-week position 37%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +8%
trailing
YTD return +8%
this year
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 28
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 5107%
annualized · 1-yr
Max drawdown −100%
past year
ATR 39.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−9% Bearish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
37% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.00% of float · ▬ 0.0% MoM · 4.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 37% Range high $1
vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NIKA
Nika Pharmaceuticals, Inc
this stock
$431.19M +7.9% — — 0.0%
TAK
Takeda Pharmaceutical Co Ltd
 $64.50B +27.8% — — 0.1%
GALDY
Galderma Group AG
 $49.23B +1.9% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $46.52B +30.2% +4.3% 65.4 2.6%
HLN
Haleon plc
 $44.06B -0.9% — — 0.6%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
70
Days to cover
4.7d
Change
0 sh
View
Short Volume
Short vol %
100%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
1.4K
Value
$400
As of
Dec 30, 2025
View
Off-Exchange
Off-exchange %
100.0%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-76.4K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 10, 2026
This year
3
View
Proposed Sales
Value
$10.0M
Shares
10.0M
Filed
Apr 16, 2025
View

Performance

5D 20D 120D MTD YTD
NIKA -19.6% +7.9% — +0.0% +7.9%
SPY +0.1% -0.4% +15.1% +0.4% +12.9%
vs SPY -19.7% +8.3% — -0.4% -5.1%
Key facts CIK 1145604 Visit website Investor relations